drugset
Drugs / rAAVrh74.MCK.micro-Dystrophin
last change Sep 2017 re-read 3 minutes ago

rAAVrh74.MCK.micro-Dystrophin

Gene therapy (AAV / viral vector)

Developed for
Duchenne muscular dystrophy
Investigated by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Jerry R. Mendell

Trials 1

today NCT02376816 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02376816 Mar 2015 → Sep 2017 Duchenne muscular dystrophy Jerry R. Mendell Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rAAVrh74.MCK.micro-Dystrophin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02376816 ↗
Action Restore “micro-Dystrophin vector as a potential dystrophin replacement mechanism” NCT02376816 ↗
Modality Gene therapy (AAV / viral vector) “Recombinant adeno-associated virus” NCT02376816 ↗
Route Intramuscular “administered by an intramuscular route” NCT02376816 ↗